Genentech's Tecentriq, Abraxane combo demonstrates positive Phase III results
Genentech, a member of the Roche, announced positive results from the Phase III IMpassion130 study of Tecentriq plus chemotherapy - Abraxane - for the initial treatment of unresectable locally advanced or metastatic triple-negative breast cancer. The Tecentriq and chemotherapy combination significantly reduced the risk of disease worsening or death compared with chemotherapy alone in all randomized patients and the PD-L1-positive population, a subgroup determined by PD-L1 biomarker testing. At this interim analysis, statistical significance was not met for overall survival in the ITT population, but showed a clinically meaningful 9.5-month OS improvement in the PD-L1-positive population. Due to the hierarchical statistical design, results in the PD-L1-positive population were not formally tested. Follow-up will continue until the next planned analysis. Safety in the Tecentriq plus nab-paclitaxel arm appeared consistent with the known safety profiles of the individual medicines, and no new safety signals were identified with the combination.